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LETTER TO THE EDITORAge and the Outcome
of Allogeneic Hematopoietic
Stem Cell Transplantation:
Was Tacitus Wrong?
As a fellow training in allogeneic bone marrow
transplantation in the early 1990s, I learned what
Tacitus apparently appreciated almost 2 millennia
before me: corpora lente augescent cito extinguuntur
(bodies grow slowly and die quickly). I was therefore
excited to see that older bodies apparently tolerate
the rigors of myeloablative allogeneic hematopoietic
stem cell transplantation (HSCT) just like younger
ones [1].
Alatrash et al. [1] are to be complimented on their
analysis of the effect of patient age on the outcome of
myeloablative allogeneic HSCT after conditioning
with busulfan and fludarabine. However, missing
information and the absence of a multivariable analysis
weaken the findings by not permitting a stringent
comparison of the various age groups.
Because the primary age groups studied were
those aged\58 and $58 years, can the authors show
a comparison of the characteristics of the 2 groups?
These are diagnosis, disease status, chemosensitivity,
cytogenetics, donor type, HLA match grade, stem
cell source, CD341 cell dose, institution, pentostatin
use, antithymocyte globulin use, hematopoietic cell
transplantation-comorbidity index, performance sta-
tus, and donor age. What were the ages of the 5
patients transplanted at the smaller center—and their
outcomes? What are the results when all the pertinent
factors are entered into a Cox analysis—and age group
is forced into the model?1878The age spread (range: 55-76, but a median of 58)
also suggests that a slightly different type of analysis is
in order. What were the event-free survival and overall
survival by the following bands of age: 55 to 60, .60
to 65, .65 to 70, and over 70? A Cox analysis of the
sort mentioned above would be useful for these age
groups as well.
It is conceivable that an imbalance in 1 or more of
these factors between groups (younger group adverse
and older group favorable) could explain the apparent
lack of effect of age in this analysis. In my opinion,
a much closer look at the data and analysis presented
in this paper—and even greater caution—are war-
ranted before starting to use intense regimens in
patients in their 60s and 70s; a number of whom
have a difficult time even with the morbidity of
nonmyeloablative allogeneic HSCT.REFERENCE
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